Fine lines/Wrinkles
Top Korean Botox Brands: Clinical Trial Data, FDA Status, and What U.S. Practices Need to Know
More clinics are stocking Korean-manufactured botulinum toxin alongside classic American brands, and the trend has been building for nearly a decade. But "Korean Botox" is not one product with one regulatory status. Some Korean-developed formulations have completed full FDA review and are sold in the United States under different trade names. Others remain widely used internationally but have no FDA pathway for U.S. clinical use at all, and the FDA has taken direct enforcement action against online sellers of at least one of them as recently as November 2025.
This guide separates the two categories, walks through the actual clinical trial data behind each major Korean brand, and explains the current U.S. regulatory picture so practices and patients can make an informed decision.
Key Takeaways
Two Korean-developed botulinum toxins have full FDA approval for U.S. clinical use: Nabota (sold in the U.S. as Jeuveau) and Botulax (sold in the U.S. as Letybo).
Jeuveau's approval rests on two Phase III trials, EV-001 and EV-002, in which 67.5% and 70.4% of patients met the primary efficacy endpoint at Day 30, versus roughly 1% in the placebo groups.
Letybo's approval rests on three Phase III trials (BLESS I, II, III) covering 1,271 patients, with treatment-success differences over placebo of 47%, 45%, and 65% respectively.
Other Korean brands sold internationally, including Innotox, Liztox, and Coretox, do not currently have FDA approval for U.S. clinical or cosmetic use.
In November 2025, the FDA sent warning letters to 18 websites illegally selling unapproved botulinum toxin products to U.S. consumers, two of which specifically involved Innotox; this followed a CDC investigation into 17 botulism-like adverse events across nine states.
The U.S. Regulatory Picture, Plainly Stated
Botulinum toxin is a prescription drug with a boxed warning, the FDA's most serious safety designation, because the toxin can spread beyond the injection site and cause symptoms of botulism. That means every brand sold for use in the U.S. has to clear FDA review under its own trade name, regardless of how well-established it is in Korea.
Right now, exactly two Korean-developed formulations have done that:
Nabota (Daewoong Pharmaceuticals) is sold in the U.S. as Jeuveau, approved in February 2019.
Botulax (Hugel) is sold in the U.S. as Letybo, approved in February 2024.
Brands like Innotox, Liztox, Coretox, Meditoxin, and Neuronox are legitimate, regulated products in their home markets, but none currently has FDA clearance for U.S. clinical use. Importing or administering them in the U.S. outside of an approved clinical trial falls outside FDA's drug approval framework.
This is not a theoretical risk. In November 2025, the FDA issued warning letters to 18 websites for illegally marketing unapproved and misbranded botulinum toxin products to U.S. consumers, citing adverse events including botulism symptoms. Two of those letters were specifically tied to the sale of Innotox. The action followed a joint FDA/CDC investigation into 17 cases across nine states between late 2023 and early 2024, where patients developed blurred or double vision, drooping eyelids, difficulty swallowing, and breathing problems after receiving injections from unverified sources; 13 were hospitalized. Practices and patients evaluating "Korean Botox" should treat that history as part of the decision, not a footnote.
Nabota / Jeuveau
Daewoong Pharmaceuticals developed Nabota, and Evolus brought it through FDA review in the United States under the name Jeuveau (prabotulinumtoxinA-xvfs). Approval was based on two identical Phase III trials, EV-001 and EV-002, registered with the FDA as randomized, multicenter, double-blind, placebo-controlled studies in 654 adults with moderate-to-severe glabellar lines.
The primary endpoint was a two-point composite improvement on the Glabellar Line Scale, agreed upon by both investigator and patient, at Day 30. Jeuveau met that endpoint in 67.5% of subjects in EV-001 and 70.4% in EV-002, compared with 1.2% and 1.3% in the respective placebo arms. Subjects were followed for 150 days, and the drug also showed a statistically significant advantage over placebo at four and five months on a secondary composite score. Longer-term safety was supported by additional studies, including a European trial (EV-003) and open-label extension studies (EV-004 and EV-006).
In practical terms: Nabota and Jeuveau are the same compound. U.S. patients are not getting a "downgraded" or different version when they receive Jeuveau through a licensed provider — they're getting the FDA-reviewed pathway for the same Korean-developed toxin sold internationally as Nabota.
Botulax / Letybo
Hugel manufactures Botulax, and in the U.S. it's marketed by Hugel America/BENEV under the name Letybo (letibotulinumtoxinA-wlbg), approved in February 2024. The approval was supported by three identical Phase III trials, BLESS I, II, and III, totaling 1,271 patients with moderate-to-severe glabellar lines, registered with the FDA as NCT02677298, NCT02677805, and NCT03985982.
The primary endpoint was treatment success at Week 4: a Glabellar Line Scale score of 0 or 1, with at least a 2-point improvement from baseline at maximum frown. Letybo outperformed placebo by 47% in BLESS I, 45% in BLESS II, and 65% in BLESS III. In the pivotal trial cited in FDA review materials, 78.6% of patients showed improvement by investigator assessment and 68.8% by self-assessment at four weeks, with a composite responder rate of 64.7% against 0% for placebo. Median time to onset was reported at around 3 days, with effects typically lasting 3 to 4 months. Open-label extension data across multiple treatment cycles showed no new safety signals.
As with Nabota/Jeuveau, Botulax and Letybo refer to the same manufacturer's formulation under different trade names depending on market.
Liztox
Liztox is manufactured by Huons Biopharma and does not currently have a U.S.-approved equivalent brand. The most relevant published clinical data comes from a randomized, double-blind, active-control Phase III trial comparing Liztox directly against onabotulinumtoxinA (Botox) in post-stroke upper-limb spasticity, a medical rather than cosmetic indication, which found comparable safety and efficacy outcomes between the two. That trial supports the pharmacologic comparability of the toxin itself, but it is not the same evidence base used for FDA glabellar-line approval, and Liztox has not gone through that U.S. review process.
Manufacturer-reported purity specifications are often cited at around 99.8% for Liztox versus roughly 98% for Botulax. These figures come from manufacturer and distributor comparison sources rather than a single independent head-to-head assay, so they're worth treating as a general formulation characteristic rather than a precisely benchmarked study result.
Innotox
Medytox developed Innotox as the first ready-to-use liquid botulinum toxin type A, approved by Korea's Ministry of Food and Drug Safety in 2013. Unlike freeze-dried formulations, it requires no reconstitution before injection. Published clinical literature on liquid-type BoNT-A formulations (the technology behind Innotox) has compared it against conventional reconstituted toxin and noted that the liquid form remains stable and usable for up to 22 months from manufacture, versus a much shorter post-reconstitution window for powder formulations.
That said, Innotox is not FDA-approved for any use in the United States, and it was one of the products named in the FDA's November 2025 warning letters to online sellers. U.S. practices should not purchase, stock, or inject Innotox, and should be cautious of marketing claims that present it as a legal alternative to FDA-approved neuromodulators for American patients. Innotox for sale to U.S. buyers is precisely the activity the FDA's November 2025 warning letters targeted, so any online listing marketing it to American patients should be read as a red flag rather than a legitimate sourcing option.
Coretox
Coretox, also from Medytox, is formulated without complexing proteins — a manufacturing approach intended to reduce the theoretical risk of antibody-related resistance over repeated treatments. This is a stated formulation characteristic rather than a result from a head-to-head resistance trial we could independently verify, so it's best presented to readers as the manufacturer's rationale rather than a proven clinical outcome. Coretox has no FDA-approved U.S. equivalent at this time.
What This Means for Pricing
For the two FDA-approved options, real-world per-unit pricing in the U.S. has been reported at roughly $9–$13 per unit for Letybo versus $12–$16 per unit for Botox, putting Letybo about 10–20% cheaper per treatment in several medical-spa pricing breakdowns. Jeuveau has followed a similar lower-cost positioning relative to Botox since its 2019 launch.
Internationally sourced, non-FDA-approved Korean originals are often cheaper again at the wholesale level in markets where they're legally sold — but that price difference reflects market and regulatory status, not a documented quality gap, and it doesn't change the fact that they currently fall outside the FDA's approval framework for U.S. use.
Bottom Line
If you're a U.S. practice or patient, the clinically and legally supported choices right now are Jeuveau (Nabota) and Letybo (Botulax), both backed by multi-trial FDA Phase III data and full U.S. regulatory clearance. Other Korean brands — Innotox, Liztox, Coretox, and similar — are legitimate products with real clinical use abroad, but none currently has a path to FDA-approved use in the United States, and at least one (Innotox) is the subject of active FDA enforcement against unauthorized U.S. sales as of late 2025. Any practice considering these products should weigh that regulatory reality alongside cost and formulation differences before making a sourcing decision.
Sources
Beer KR, et al. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies (EV-001, EV-002). Dermatologic Surgery. 2019. DOI: 10.1097/DSS.0000000000001903
FDA Drug Trials Snapshots — LETYBO (letibotulinumtoxinA-wlbg), Hugel Inc., approved February 29, 2024. BLESS I–III (NCT02677298, NCT02677805, NCT03985982). fda.gov
Ye DH, et al. A Randomized, Double-Blind, Active Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Liztox® versus Botox® in Post-Stroke Upper Limb Spasticity. Toxins (Basel). 2023;15(12):697. DOI: 10.3390/toxins15120697. PMID: 38133201
Shin J, et al. The Efficacy and Safety of Liquid-Type Botulinum Toxin Type A for the Management of Moderate to Severe Glabellar Frown Lines. Dermatologic Surgery. 2015;41(1):54–62. DOI: 10.1097/DSS.0000000000000219
FDA Press Announcement. FDA Warns Companies Over Illegal Marketing of Botox and Related Products. November 5, 2025. fda.gov
FDA Warning Letter — MJS Medicals (Innotox 100ui/100u), November 3, 2025. fda.gov